Kamada Bundle
Who owns Kamada Ltd. today?
Kamada Ltd., an Israeli plasma‑derived biologics company founded in 1990, shifted from founder control to a diversified public ownership after its 2013 NASDAQ IPO and recent strategic deals. By FY2024 it reported about $150–170 million in annual revenue and operates globally.
Key owners now include a majority free float across NASDAQ (KMDA) and TASE, plus founder and institutional stakes, healthcare funds, and strategic partners following the Biotest-related transactions.
See product strategy and competitive dynamics in Kamada Porter's Five Forces Analysis
Who Founded Kamada?
Founders and early ownership of Kamada began in 1990 with David Tsur as the core founding entrepreneur alongside early technical and medical teams that established the plasma fractionation platform in the Negev; initial equity was concentrated among founders and a small circle of Israeli angels and friends-and-family investors.
Founding leadership
David Tsur led formation; early technical leadership included the team that preceded current CEO/chemist Amir London.
Equity concentration
Initial cap table reflected founder control exceeding a simple majority in the 1990s, with limited outside minority stakes.
Investor types
Early backers were local life-science financiers, strategic distribution partners and Israeli angels typical of the era.
Share terms
Grants reportedly used ordinary shares with four-year vesting and a one-year cliff, plus buy-sell and ROFR clauses to protect control and IP.
Financing use
Early seed and growth rounds funded the Negev fractionation facility and GMP capabilities, causing incremental dilution.
Pre-IPO liquidity
Founder partial secondary sales and liquidity events occurred before and around the IPO to broaden the register and finance expansion.
Contemporaneous sources and regulatory filings indicate founders retained protective supermajority provisions over IP transfer, major capital expenditures and partner approvals; for context on company history see Brief History of Kamada.
Key takeaways on early ownership
Founders and early investors set a governance and capital structure that prioritized a specialty plasma platform and long-term quality control.
- Founding led by David Tsur with technical/medical co-founders from initial plasma program.
- Early equity concentrated among founders and Israeli angels; founder control exceeded simple majority in the 1990s.
- Standard early-stage Israeli vesting: four-year vesting with one-year cliff, plus ROFR and buy-sell protections.
- Incremental dilution from seed/expansion rounds and pre-IPO secondary sales broadened shareholder base while preserving founder protections.
Kamada SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Kamada’s Ownership Changed Over Time?
Key events shaping Kamada ownership include pre-IPO Israeli life‑science financings (2005–2012), the 2013 NASDAQ IPO (KMDA) that expanded the free float, institutional register growth through 2014–2019, strategic U.S. plasma and partner transactions in 2020–2022, and a broadly dispersed shareholder base by 2024–2025 with no disclosed controlling owner.
| Period | Ownership shift | Impact |
|---|---|---|
| 2005–2012 | Founders diluted below majority via life‑science investors and distributors | Capital for AATD scale‑up and contract manufacturing; reduced founder control |
| 2013 (IPO) | NASDAQ listing (KMDA) increased free float; initial market cap in first trading year around $200–$600M | Attracted U.S. healthcare funds; greater liquidity |
| 2014–2019 | Institutionalization: Israeli pension/provident funds, mutuals, small‑cap healthcare managers | Founders sold via secondaries; register diversified |
| 2020–2022 | Commercial tie‑ups with Biotest/Grifols ecosystem; expanded U.S. plasma collection | Cross‑holdings and long‑term contracts reinforced commercial position without creating control |
| 2023–2025 | Broad dispersion; largest institutions hold sub‑10% each; insiders single‑digit ownership | Free float estimated above 70%; governance more consensus‑driven |
SEC 20‑F and TASE filings through 2024–2025 show typical disclosed positions in the 3–9% range for major institutions; any >5% holder is publicly reported, and holdings have rotated among global small‑cap/healthcare funds, Israeli pension vehicles and index/ETF providers.
Kamada ownership: current register traits
Ownership is diversified with institutional concentration but no single controlling shareholder; focus shifted to profitability, U.S. market and supply reliability.
- Free float estimated above 70%
- Largest shareholders are institutions holding generally under 10% each
- Insider ownership (management/directors) in the single digits collectively
- Passive ETF/index ownership modestly increased with improved liquidity
For a sector and competitor view that contextualizes Kamada shareholders and strategic moves, see Competitors Landscape of Kamada
Kamada PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Kamada’s Board?
The current board of directors of Kamada includes a majority of independent directors alongside executive leadership; CEO Amir London serves as an executive director and founder David Tsur has historically held director roles, with committees chaired by independent Israeli and international finance and industry experts.
| Director | Role / Expertise | Committee Chairs |
|---|---|---|
| Amir London | CEO, Executive Director — Biopharma operations | — |
| David Tsur | Founder / Former leadership roles — Plasma supply-chain | — |
| Independent Director A | Biopharma industry veteran (Israel) | Compensation Committee |
| Independent Director B | International pharma executive | Audit Committee |
| Independent Director C | Finance / capital markets expert | Audit Committee |
Board composition is designed to balance operational leadership with independent oversight under Israeli Companies Law and NASDAQ rules; specific seats linked to large shareholders rotate as institutional holders change and no single shareholder currently reports explicit board appointment rights beyond standard nomination processes.
Board control and voting mechanics
Voting uses a one-share-one-vote model with ordinary shares; there is no dual-class or golden share structure reported through 2024, and no successful proxy contests recorded through 2024.
- Quorum and supermajority thresholds for certain bylaw amendments follow Israeli corporate practice
- Governance issues to 2024 centered on executive compensation alignment and capital deployment, resolved via annual votes
- No disclosed single shareholder holds board appointment rights exceeding customary nomination processes
- For ownership context and shareholder trends see Growth Strategy of Kamada
Kamada Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Kamada’s Ownership Landscape?
From 2021 through mid‑2025 Kamada ownership shifted gradually toward institutional and passive holders while insiders remained in the low single digits; expansion of U.S. plasma collection and product licensing funded by operating cash flow limited dilutive equity issuance and major ownership change.
| Period | Key ownership trend | Notable metric |
|---|---|---|
| 2021–2022 | Growth funded via operating cash flow; modest balance‑sheet flexibility; limited new equity issuance | Revenue near mid‑$100M by 2022 |
| 2023 | U.S. plasma collection expansion increased vertical integration; passive index weight rose | Higher institutional ownership; insider stakes low single digits |
| 2024–mid‑2025 | Product portfolio additions via licensing/acquisition; disciplined M&A policy emphasized | Share repurchases modest; no privatization or controlling bids disclosed |
Industry consolidation among plasma players and growth of specialist healthcare funds translated into turnover among active small‑cap funds in Kamada shareholders, with analysts citing new indications, U.S. commercial scale and BD partnerships as potential catalysts to attract strategic investors; see further company business detail at Revenue Streams & Business Model of Kamada.
Institutional concentration
Passive index funds and healthcare ETFs increased weight in Kamada, raising institutional ownership proportions over 2021–2025.
Insider holdings
Insider ownership has stayed in the low single digits, indicating no founder re‑accumulation or control shift through mid‑2025.
Share buybacks
Buybacks were discussed intermittently; executed repurchases were modest relative to market cap and mainly offset employee equity dilution.
Potential catalysts
Analysts identify new indications, U.S. commercial scale and BD partnerships as triggers that could change Kamada ownership profile by attracting strategic or larger institutional investors.
Kamada Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Kamada Company?
- What is Competitive Landscape of Kamada Company?
- What is Growth Strategy and Future Prospects of Kamada Company?
- How Does Kamada Company Work?
- What is Sales and Marketing Strategy of Kamada Company?
- What are Mission Vision & Core Values of Kamada Company?
- What is Customer Demographics and Target Market of Kamada Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.